Today's Low
₹ 581.50
Today's High
₹ 589.50
52 Weeks Low
₹ 255.00
52 Weeks High
₹ 412.90
Lower
₹ 474.65
Upper
₹ 711.95
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 391.1 | 373.1 | 327.7 | 262.7 | 239.1 | 226.9 | 189.6 | 147.0 | 181.2 | 149.1 | 123.2 | 121.6 |
Total Non-Current Assets | 245.4 | 181.5 | 159.6 | 173.9 | 159.4 | 136.1 | 134.3 | 127.8 | 80.6 | 110.7 | 113.7 | 90.7 |
Total Assets | 636.5 | 554.6 | 487.3 | 436.6 | 398.5 | 363.0 | 323.9 | 274.8 | 261.9 | 259.8 | 236.9 | 212.3 |
Total Current Liabilities | 96.2 | 110.7 | 94.8 | 80.3 | 100.4 | 113.5 | 99.4 | 100.3 | 114.5 | 131.1 | 118.3 | 104.9 |
Total Non-Current Liabilities | 37.9 | 11.0 | 26.1 | 42.9 | 28.4 | 24.9 | 31.8 | 33.7 | 33.1 | 26.2 | 25.1 | 22.4 |
Shareholder's Funds | 502.5 | 432.9 | 366.4 | 313.1 | 269.3 | 224.2 | 192.4 | 140.5 | 111.3 | 98.8 | 89.3 | 80.8 |
Total Liabilities | 636.5 | 554.6 | 487.3 | 436.6 | 398.5 | 363.0 | 323.9 | 274.8 | 261.9 | 259.8 | 236.9 | 212.3 |
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 3.27, which results in a Positive aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.02, which results in a Positive aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 2.68, which results in a Positive aspect.
The Industry Price to BV stands at 6.03, vs the Price to BV of 2.02, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 510.3 | 472.1 | 424.2 | 386.5 | 366.2 | 360.6 | 360.3 | 400.2 | 266.1 | 210.5 | 194.7 | 187.6 |
Total Expenditure | 421.1 | 376.6 | 337.0 | 321.0 | 298.9 | 308.3 | 313.5 | 359.6 | 240.5 | 190.4 | 179.2 | 174.1 |
Operating Profit(Excl OI) | 111.7 | 105.5 | 92.8 | 76.6 | 72.9 | 57.8 | 49.5 | 47.9 | 32.8 | 22.6 | 21.9 | 16.9 |
Add: Other Income | 22.5 | 10.0 | 5.7 | 11.0 | 5.6 | 5.5 | 2.8 | 7.4 | 7.2 | 2.5 | 6.4 | 3.4 |
Operating Profit | 111.7 | 105.5 | 92.8 | 76.6 | 72.9 | 57.8 | 49.5 | 47.9 | 32.8 | 22.6 | 21.9 | 16.9 |
Less: Interest | 2.0 | 1.5 | 1.6 | 2.0 | 4.0 | 5.4 | 6.7 | 10.0 | 8.4 | 7.0 | 7.8 | 7.6 |
PBDT | 109.7 | 104.0 | 91.3 | 74.6 | 68.9 | 52.4 | 42.9 | 37.9 | 24.4 | 15.6 | 14.0 | 9.3 |
Less: Depreciation Amortization | 9.2 | 8.1 | 7.6 | 7.3 | 6.7 | 6.1 | 5.5 | 4.9 | 4.6 | 3.5 | 2.7 | 1.9 |
PBT & Exceptional Items | 100.5 | 95.9 | 83.7 | 67.2 | 62.2 | 46.3 | 37.3 | 33.1 | 19.9 | 12.1 | 11.4 | 7.3 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 100.5 | 95.9 | 83.7 | 67.2 | 62.2 | 46.3 | 37.3 | 33.1 | 19.9 | 12.1 | 11.4 | 7.3 |
Less: Taxation | 27.6 | 26.6 | 21.5 | 15.8 | 13.5 | 11.6 | 9.2 | 9.3 | 4.8 | 1.9 | 1.9 | 2.2 |
Profit After Tax | 72.9 | 69.4 | 62.3 | 51.5 | 48.7 | 34.7 | 28.1 | 23.8 | 15.0 | 10.2 | 9.5 | 5.1 |
Earnings Per Share | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PAT Growth stands at 32.18, vs the PAT Growth of 5.60, which results in a Negative aspect.
The Industry PAT Margin stands at 9.77, vs the PAT Margin of 12.88, which results in a Positive aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 13.31, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.26, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 100.5 | 95.9 | 83.7 | 67.2 | 62.2 | 46.2 | 37.3 | 33.1 | 19.8 | 12.1 | 9.5 | 5.1 |
Tax Paid | -29.6 | -23.7 | -19.5 | -14.8 | -17.5 | -9.2 | -9.7 | -6.8 | -3.5 | -2.6 | -1.7 | -1.2 |
Adjustment | -0.2 | 1.5 | 4.8 | 8.7 | 9.3 | 11.6 | 10.7 | 13.8 | 10.7 | 12.8 | 9.0 | 14.3 |
Changes In Working Capital | 100.5 | 95.9 | 83.7 | 67.2 | 62.2 | 46.2 | 37.3 | 33.1 | 19.8 | 12.1 | 9.5 | 5.1 |
Cash Flow after changes in Working Capital | 68.9 | 99.8 | 88.8 | 90.2 | 70.4 | 35.9 | 34.8 | 51.6 | 28.0 | 7.3 | -13.9 | 13.1 |
Cash Flow from Operating Activities | 39.3 | 76.1 | 69.3 | 75.4 | 52.8 | 26.6 | 25.0 | 44.8 | 24.6 | 4.6 | -15.6 | 11.9 |
Cash Flow from Investing Activities | -36.6 | -78.1 | -64.2 | -30.9 | -18.2 | -11.8 | -25.5 | -41.8 | 6.5 | 1.5 | -16.3 | -27.2 |
Cash Flow from Financing Activities | -4.5 | -2.6 | -5.7 | -37.8 | -35.8 | -11.4 | 0.3 | -3.4 | -32.0 | -10.5 | 29.3 | 16.2 |
Net Cash Inflow / Outflow | -1.9 | -4.5 | -0.7 | 6.8 | -1.1 | 3.5 | -0.1 | -0.4 | -1.0 | -4.4 | -2.6 | 0.8 |
Opening Cash & Cash Equivalents | 6.9 | 11.4 | 12.1 | 5.5 | 6.6 | 3.1 | 3.3 | 3.7 | 4.8 | 9.4 | 12.0 | 11.5 |
Closing Cash & Cash Equivalent | 5.1 | 6.9 | 11.4 | 12.2 | 5.5 | 6.6 | 3.1 | 3.4 | 3.9 | 5.0 | 9.4 | 12.4 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 4.09, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 3.55, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 1,464.5 | 1,559.9 | 1,356.2 | 1,124.6 | 1,337.7 | 1,406.1 | 1,234.7 | 1,025.9 | 1,198.8 | 1,274.7 | 1,221.9 | 795.8 | 1,147.5 | 1,260.6 | 1,037.9 | 784.7 |
Total Income | 1,574.7 | 1,646.8 | 1,433.1 | 1,163.6 | 1,401.2 | 1,463.3 | 1,299.7 | 1,044.8 | 1,225.2 | 1,309.3 | 1,242.0 | 821.2 | 1,154.8 | 1,266.7 | 1,055.9 | 826.5 |
Total Expenditure | 1,167.9 | 1,248.4 | 1,149.0 | 958.2 | 1,070.1 | 1,117.1 | 1,065.6 | 851.4 | 964.3 | 982.0 | 968.8 | 643.4 | 947.4 | 963.0 | 816.3 | 698.5 |
PBIDT (Excl OI) | 296.6 | 311.5 | 207.2 | 166.4 | 267.5 | 289.0 | 169.1 | 174.5 | 234.5 | 292.7 | 253.1 | 152.4 | 200.0 | 297.6 | 221.7 | 86.2 |
Other Income | 110.2 | 87.0 | 76.9 | 39.0 | 63.6 | 57.2 | 65.0 | 18.9 | 26.4 | 34.6 | 20.1 | 25.4 | 7.3 | 6.0 | 18.0 | 41.9 |
Operating Profit | 406.8 | 398.4 | 284.1 | 205.4 | 331.1 | 346.2 | 234.1 | 193.4 | 260.9 | 327.3 | 273.2 | 177.8 | 207.3 | 303.7 | 239.7 | 128.0 |
Interest | 1.6 | 3.9 | 4.2 | 11.5 | 3.3 | 1.4 | 4.1 | 5.7 | 3.1 | 2.0 | 3.8 | 5.8 | 3.9 | -0.8 | 6.7 | -5.6 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 405.2 | 394.5 | 279.9 | 193.9 | 327.8 | 344.8 | 230.0 | 187.7 | 257.8 | 325.3 | 269.5 | 172.0 | 203.4 | 304.4 | 232.9 | 133.6 |
Depreciation | 28.1 | 25.8 | 25.5 | 24.1 | 22.6 | 24.2 | 20.7 | 20.0 | 21.8 | 19.9 | 19.2 | 18.9 | 19.0 | 19.0 | 18.8 | 18.3 |
Profit Before Tax | 377.1 | 368.7 | 254.5 | 169.8 | 305.2 | 320.6 | 209.3 | 167.7 | 236.0 | 305.4 | 250.3 | 153.1 | 184.4 | 285.5 | 214.1 | 115.3 |
Tax | 96.7 | 92.1 | 64.3 | 44.2 | 89.0 | 83.5 | 59.1 | 57.5 | 60.0 | 75.1 | 73.3 | 27.3 | 49.6 | 76.3 | 61.5 | 25.9 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 280.4 | 276.5 | 190.1 | 125.6 | 216.1 | 237.1 | 150.1 | 110.3 | 176.0 | 230.3 | 177.0 | 125.8 | 134.9 | 209.2 | 152.6 | 89.4 |
Net Profit | 280.4 | 276.5 | 190.1 | 125.6 | 216.1 | 237.1 | 150.1 | 110.3 | 176.0 | 230.3 | 177.0 | 125.8 | 134.9 | 209.2 | 152.6 | 89.4 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 200.3 | 200.3 | 200.3 | 200.3 | 200.3 | 200.3 | 200.3 | 200.3 | 200.3 | 200.0 | 200.0 | 200.0 | 200.0 | 200.0 | 200.0 | 200.0 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 14.0 | 13.8 | 9.5 | 6.3 | 10.8 | 11.8 | 7.5 | 5.5 | 8.8 | 11.5 | 8.9 | 6.3 | 6.7 | 10.5 | 7.6 | 4.5 |
Operating Profit Margin | 27.8 | 25.5 | 20.9 | 18.3 | 24.8 | 24.6 | 19.0 | 18.8 | 21.8 | 25.7 | 22.4 | 22.3 | 18.1 | 24.1 | 23.1 | 16.3 |
Net Profit Margin | 19.1 | 17.7 | 14.0 | 11.2 | 16.2 | 16.9 | 12.2 | 10.7 | 14.7 | 18.1 | 14.5 | 15.8 | 11.8 | 16.6 | 14.7 | 11.4 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of 5.56, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -37.05, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 629.90 | 651.28 | 595.25 |
R3 | 616.27 | 617.95 | 588.67 |
R2 | 602.63 | 603.48 | 586.48 |
R1 | 592.37 | 594.05 | 584.29 |
Pivot | 578.73 | 579.58 | 578.73 |
S1 | 568.47 | 570.15 | 579.91 |
S2 | 554.83 | 555.68 | 577.72 |
S3 | 544.57 | 546.25 | 575.53 |
S4 | 534.30 | 507.88 | 568.96 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
57.00
Neutral
RSI
38.77
Neutral
ROC
-3.84
Bearish
UltimateOscillator
46.94
Neutral
Williams Indicator
-54.64
Neutral
CCI Indicator
-77.95
Neutral
MACD
-2,471.09
Bearish
Stochastic Indicator
38.51
Neutral
ATR
22.83
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
15-09-2023 | 1.50 | 15 | Final |
15-09-2022 | 1.50 | 15 | Final |
16-09-2021 | 1.50 | 15 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
08-02-2024 | Quarterly Results |
02-11-2023 | Quarterly Results |
10-08-2023 | Quarterly Results |
25-05-2023 | Dividend & Audited Results |
09-02-2023 | Quarterly Results |
10-11-2022 | Quarterly Results |
09-08-2022 | Quarterly Results |
19-05-2022 | Dividend |
10-02-2022 | Quarterly Results |
11-11-2021 | Quarterly Results |
05-10-2021 | inter-alia to transact the following businesses: 1) To issue/ allot equity shares to the eligible shareholders of Lincoln Parenteral Ltd. pursuant to Scheme of Amalgamation of Lincoln Parenteral Limited ('Transferor Company') and Lincoln Pharmaceuticals Limited ('Transferee Company') and their respective shareholders and creditors, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 as approved by the Hon'ble National Company Law Tribunal, Ahmedabad Bench vide its order dated September 14, 2021. 2) Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting, if any. |
10-08-2021 | Quarterly Results |
25-05-2021 | LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended on March 31, 2021 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any. Further, in continuation to our disclosure on closure of trading window dated March 31, 2021, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally available. |